ERG and prostate neoplasm: ERG is overexpressed in 40%–50% of primary prostate tumours [26], with ETS gene rearrangements—mainly TMPRSS2-ERG fusion (>90% ETS rearrangements)—described in 30%–50% of patients with newly-diagnosed, untreated PCa [27].